Yong Jie Ning, Lim Wen Hui, Ng Cheng Han, Tan Darren Jun Hao, Xiao Jieling, Tay Phoebe Wen Lin, Lin Snow Yunni, Syn Nicholas, Chew Nicholas, Nah Benjamin, Dan Yock Young, Huang Daniel Q, Tan Eunice Xiang Xuan, Sanyal Arun J, Noureddin Mazen, Siddiqui Mohammad Shadab, Muthiah Mark D
Yong Loo Lin School of Medicine.
Department of Cardiology, National University Heart Centre.
Clin Gastroenterol Hepatol. 2023 Jan;21(1):45-54.e6. doi: 10.1016/j.cgh.2021.11.014. Epub 2021 Nov 18.
BACKGROUND & AIMS: Nonalcoholic steatohepatitis (NASH) is the fastest growing indication of liver transplantation (LT) and is projected to be the leading cause of LT in the near future. The systemic pathogenesis of NASH increases risks of adverse clinical outcomes in patients with NASH receiving LT. Thus, this study aimed to conduct a time-dependent survival analysis between LT recipients with and without NASH using hazard ratios.
A search was conducted on Medline and Embase databases for articles relating to LT outcomes for NASH recipients. A survival analysis was conducted of hazard ratios using the DerSimonian and Laird random-effects model with meta-regression. To account for censoring, survival data were reconstructed from published Kaplan-Meier curves and pooled to derive more accurate hazard estimates and all-cause mortality in NASH patients after LT. Pairwise meta-analysis was conducted to analyze secondary outcomes.
Fifteen studies involving 119,327 LT recipients were included in our analysis with a prevalence of NASH of 20.2% (95% CI, 12.9-30.2). The pooled 1-year, 5-year, and 10-year all-cause mortality in NASH patients after LT were 12.5%, 24.4%, and 37.9%, respectively. Overall survival was comparable between LT recipients for NASH vs non-NASH (hazard ratio, 0.910; 95% CI, 0.760 to 1.10; P = .34). Meta-regression showed that a higher model for end-stage liver disease score was associated with significantly worse overall survival in NASH compared with non-NASH after LT (95% CI, -0.0856 to -0.0181; P = .0026).
This study shows that patients undergoing LT for NASH cirrhosis have comparable complication rates, overall survival, and graft survival compared with non-NASH patients, although close monitoring may be indicated for those with higher model for end-stage liver disease scores.
非酒精性脂肪性肝炎(NASH)是肝移植(LT)中增长最快的适应证,预计在不久的将来将成为LT的主要原因。NASH的全身发病机制增加了接受LT的NASH患者出现不良临床结局的风险。因此,本研究旨在使用风险比在有和没有NASH的LT受者之间进行时间依赖性生存分析。
在Medline和Embase数据库中搜索与NASH受者LT结局相关的文章。使用DerSimonian和Laird随机效应模型及元回归对风险比进行生存分析。为了考虑删失,从已发表的Kaplan-Meier曲线重建生存数据并汇总,以得出更准确的风险估计值和LT后NASH患者的全因死亡率。进行成对元分析以分析次要结局。
我们的分析纳入了15项研究,涉及119327名LT受者,NASH患病率为20.2%(95%CI,12.9 - 30.2)。LT后NASH患者的汇总1年、5年和10年全因死亡率分别为12.5%、24.4%和37.9%。NASH与非NASH的LT受者总体生存率相当(风险比,0.910;95%CI,0.760至1.10;P = 0.34)。元回归显示,与LT后的非NASH相比,NASH中终末期肝病评分较高的模型与总体生存率显著更差相关(95%CI,-0.0856至-0.0181;P = 0.0026)。
本研究表明,与非NASH患者相比,因NASH肝硬化接受LT的患者并发症发生率、总体生存率和移植物生存率相当,尽管对于终末期肝病评分较高的患者可能需要密切监测。